Amgen (NASDAQ:AMGN) Given New $295.00 Price Target at Deutsche Bank Aktiengesellschaft

Amgen (NASDAQ:AMGN) had its target price boosted by Deutsche Bank Aktiengesellschaft from $285.00 to $295.00 in a report released on Thursday morning,MarketScreener reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the medical research company’s stock.

AMGN has been the topic of a number of other research reports. BMO Capital Markets lifted their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a report on Wednesday, December 3rd. HSBC reaffirmed a “buy” rating and set a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Royal Bank Of Canada increased their target price on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, Leerink Partners boosted their price target on shares of Amgen from $305.00 to $355.00 and gave the stock an “outperform” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $348.09.

Amgen Trading Up 2.2%

Shares of AMGN stock opened at $376.02 on Thursday. The company has a market cap of $202.48 billion, a PE ratio of 26.35, a P/E/G ratio of 3.20 and a beta of 0.46. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.99 and a current ratio of 1.14. Amgen has a fifty-two week low of $261.43 and a fifty-two week high of $374.90. The stock’s fifty day moving average price is $333.66 and its two-hundred day moving average price is $310.84.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period last year, the company posted $5.31 EPS. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.7%. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is presently 66.90%.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This trade represents a 11.16% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 10,908 shares of company stock valued at $3,674,966 in the last 90 days. 0.76% of the stock is currently owned by corporate insiders.

Institutional Trading of Amgen

Several hedge funds have recently bought and sold shares of AMGN. Dogwood Wealth Management LLC lifted its position in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares in the last quarter. Anfield Capital Management LLC raised its position in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares during the last quarter. Board of the Pension Protection Fund bought a new position in Amgen during the 4th quarter valued at $26,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the 2nd quarter worth $27,000. Finally, Manning & Napier Advisors LLC grew its stake in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.